The c.7847C>T variant in BRCA2 is a missense variant predicted to cause substitution of serine by phenylalanine at amino acid 2616 (p.(Ser2616Phe)). This variant is absent from gnomAD v2.1 (exomes only, non-cancer subset, read depth ≥25) and gnomAD v3.1 (non-cancer subset, read depth ≥25) (PM2_Supporting met). This BRCA2 missense variant is within a key functional domain and the computational predictor BayesDel (noAF) gives a score of 0.12, which is below the recommended threshold of 0.18 for predicting no impact on BRCA2 via protein change. A SpliceAI score of 0.05 predicts no impact on splicing (score threshold ≤0.1) (BP4 met). Reported by 4 calibrated studies to exhibit protein function similar to pathogenic control variants (PMIDs: 38417439, 32444794, 39779857, 39779848) (PS3 met). Cosegregation analysis of 9 families carrying this variant provided evidence towards pathogenicity, and has a Bayes Score of 58.44 (applied as LR), within the thresholds for Strong pathogenic evidence (LR ≥18.7 & <350) (PP1_Strong met; PMID:41856558). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 15.58 (based on Pathology LR=15.58), within the thresholds for moderate evidence towards pathogenicity (LR ≥4.3 & <18.7) (PP4_Moderate met; PMID:41856558). This variant has been detected in 1 individual with phenotype consistent with BRCA2-Fanconi Anemia (FA). At least one clinical feature of FA (physical features) and confirmed chromosome breakage are seen in this individual. This individual was compound heterozygous for the variant and a pathogenic or likely pathogenic variant BRCA2:c.475+1G>A, which was confirmed to be in trans. Total points equated to 2 (PM3 met; PMID:30792206). In summary, this variant meets the criteria to be classified as a Pathogenic variant for BRCA2-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (v1.2) (PM2_Supporting, BP4, PS3, PM3, PP1_Strong, PP4_Moderate).